



February 13, 2017

## **Supernus to Host Fourth Quarter and Full Year 2016 Earnings Conference Call**

ROCKVILLE, Md., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial results for the fourth quarter and full year of 2016 after 5:00 PM ET on Tuesday, February 28, 2017.

Jack Khattar, President and Chief Executive Officer, and Greg Patrick, Chief Financial Officer, will host a conference call to present the fourth quarter and full year 2016 results on Wednesday, March 1, 2017 at 9:00 AM ET. Following the presentation, the call will be open for questions.

A live webcast will be available at [www.supernus.com](http://www.supernus.com).

Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.

Conference dial-in: (877) 288-1043  
International dial-in: (970) 315-0267  
Conference ID: 70744734  
Conference Call Name: Supernus Pharmaceuticals Fourth Quarter and Full Year 2016 Earnings Conference Call

Following the live call, a replay will be available on the Company's website under the 'Investors' section. The webcast will be available on the Company's website for 60 days following the live call.

### **About Supernus Pharmaceuticals, Inc.**

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of impulsive aggression in ADHD patients and SPN-812 for the treatment of ADHD.

#### CONTACTS:

Jack A. Khattar, President and CEO

Gregory S. Patrick, Vice President and CFO

Supernus Pharmaceuticals, Inc.

Tel: (301) 838-2591

or

#### INVESTOR CONTACT:

Peter Vozzo

Westwicke Partners

Office: (443) 213-0505

Mobile: (443) 377-4767

Email: [peter.vozzo@westwicke.com](mailto:peter.vozzo@westwicke.com)

 Primary Logo

Source: Supernus Pharmaceuticals, Inc.

News Provided by Acquire Media